BR112016024546A2 - anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica - Google Patents
anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêuticaInfo
- Publication number
- BR112016024546A2 BR112016024546A2 BR112016024546-6A BR112016024546A BR112016024546A2 BR 112016024546 A2 BR112016024546 A2 BR 112016024546A2 BR 112016024546 A BR112016024546 A BR 112016024546A BR 112016024546 A2 BR112016024546 A2 BR 112016024546A2
- Authority
- BR
- Brazil
- Prior art keywords
- antibody
- fragment
- antibody fragment
- nucleic acid
- pharmaceutical composition
- Prior art date
Links
- 102000008394 Immunoglobulin Fragments Human genes 0.000 title abstract 3
- 108010021625 Immunoglobulin Fragments Proteins 0.000 title abstract 3
- 239000000611 antibody drug conjugate Substances 0.000 title 1
- 229940049595 antibody-drug conjugate Drugs 0.000 title 1
- 150000007523 nucleic acids Chemical class 0.000 title 1
- 102000039446 nucleic acids Human genes 0.000 title 1
- 108020004707 nucleic acids Proteins 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 208000034578 Multiple myelomas Diseases 0.000 abstract 1
- 101100425747 Mus musculus Tnfrsf17 gene Proteins 0.000 abstract 1
- 206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000003993 interaction Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 210000004180 plasmocyte Anatomy 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
- A61K47/6867—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from a cell of a blood cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/54—F(ab')2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Mycology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Physical Education & Sports Medicine (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Transplantation (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Peptides Or Proteins (AREA)
Abstract
a invenção se refere a anticorpos ou fragmentos de anticorpos humanizados que se ligam ao cd269 (bcma), interrompendo assim a interação entre o cd269 e seus ligantes nativos (baff e april) e ao seu uso no tratamento de doenças mediadas por células plasmáticas, tais como o mieloma múltiplo e doenças autoimunes.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14166729.5 | 2014-04-30 | ||
EP14166729 | 2014-04-30 | ||
PCT/EP2015/059562 WO2015166073A1 (en) | 2014-04-30 | 2015-04-30 | Humanized antibodies against cd269 (bcma) |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112016024546A2 true BR112016024546A2 (pt) | 2018-01-23 |
Family
ID=50677985
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112016024546-6A BR112016024546A2 (pt) | 2014-04-30 | 2015-04-30 | anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica |
Country Status (16)
Country | Link |
---|---|
US (3) | US10144782B2 (pt) |
EP (1) | EP3137500A1 (pt) |
JP (3) | JP6755805B2 (pt) |
KR (3) | KR102526945B1 (pt) |
CN (2) | CN106661109B (pt) |
AU (1) | AU2015254526B2 (pt) |
BR (1) | BR112016024546A2 (pt) |
CA (1) | CA2944962A1 (pt) |
IL (2) | IL303667A (pt) |
MX (2) | MX2016013767A (pt) |
NZ (1) | NZ725701A (pt) |
RU (2) | RU2021115081A (pt) |
SG (1) | SG11201608415QA (pt) |
UA (1) | UA121031C2 (pt) |
WO (1) | WO2015166073A1 (pt) |
ZA (1) | ZA201607018B (pt) |
Families Citing this family (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3508503B1 (en) | 2012-11-01 | 2022-11-02 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Antibody against cd269 (bcma) |
CA2900529A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
NZ725701A (en) * | 2014-04-30 | 2023-09-29 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
CN107980046B (zh) | 2015-04-13 | 2021-12-24 | 辉瑞公司 | 靶向b细胞成熟抗原的嵌合抗原受体 |
EP3283106B1 (en) | 2015-04-13 | 2021-12-22 | Pfizer Inc. | Therapeutic antibodies and their uses |
US11698369B2 (en) | 2016-01-12 | 2023-07-11 | Oncotracker, Inc. | Methods for monitoring immune status of a subject |
JP7152309B2 (ja) * | 2016-02-17 | 2022-10-12 | シージェン インコーポレイテッド | 癌及び免疫学的障害を治療するためのbcma抗生物質及びその使用 |
AU2017276706A1 (en) | 2016-06-07 | 2019-01-03 | Max-Delbrück-Centrum Für Molekulare Medizin In Der Helmholtz-Gemeinschaft | Chimeric antigen receptor and CAR-T cells that bind BCMA |
EA201891851A1 (ru) * | 2016-09-16 | 2019-04-30 | Сиэтл Дженетикс, Инк. | Антитела против bcma и их применение для лечения злокачественных новообразований и иммунологических нарушений |
WO2018115466A1 (en) * | 2016-12-23 | 2018-06-28 | Heidelberg Pharma Research Gmbh | Amanitin antibody conjugates |
CN108285489A (zh) * | 2017-01-09 | 2018-07-17 | 上海恒润达生生物科技有限公司 | 靶向BCMA-BBz-tEGFR的嵌合抗原受体及其用途 |
US20190375815A1 (en) | 2017-01-31 | 2019-12-12 | Novartis Ag | Treatment of cancer using chimeric t cell receptor proteins having multiple specificities |
CN108395478A (zh) * | 2017-02-04 | 2018-08-14 | 上海恒润达生生物科技有限公司 | 靶向bcma的嵌合抗原受体并对其双重修饰的方法及其用途 |
ES2949364T3 (es) | 2017-02-17 | 2023-09-28 | Fred Hutchinson Cancer Center | Terapias de combinación para el tratamiento de cánceres y trastornos autoinmunitarios relacionados con BCMA |
EP3615068A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
EP3615055A1 (en) | 2017-04-28 | 2020-03-04 | Novartis AG | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
WO2019035938A1 (en) | 2017-08-16 | 2019-02-21 | Elstar Therapeutics, Inc. | MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF |
JP2021501570A (ja) | 2017-10-18 | 2021-01-21 | ノバルティス アーゲー | 選択的タンパク質分解のための組成物及び方法 |
RU2020119365A (ru) | 2017-11-15 | 2021-12-13 | Новартис Аг | Химерный антигенный рецептор, нацеливающийся на всма, химерный антигенный рецептор, нацеливающийся на cd19, и средства комбинированной терапии |
US20200371091A1 (en) | 2017-11-30 | 2020-11-26 | Novartis Ag | Bcma-targeting chimeric antigen receptor, and uses thereof |
TW201930591A (zh) | 2018-01-08 | 2019-08-01 | 瑞士商諾華公司 | 用於與嵌合抗原受體療法併用之免疫增強rna |
EP3746116A1 (en) | 2018-01-31 | 2020-12-09 | Novartis AG | Combination therapy using a chimeric antigen receptor |
CN111601825B (zh) | 2018-02-01 | 2022-11-29 | 信达生物制药(苏州)有限公司 | 全人源的抗b细胞成熟抗原(bcma)单链抗体及其应用 |
WO2019160956A1 (en) | 2018-02-13 | 2019-08-22 | Novartis Ag | Chimeric antigen receptor therapy in combination with il-15r and il15 |
EA202091974A1 (ru) * | 2018-02-21 | 2020-12-08 | Селджин Корпорейшн | Связывающие bcma антитела и их применение |
KR20210016390A (ko) | 2018-06-01 | 2021-02-15 | 노파르티스 아게 | Bcma에 대한 결합 분자 및 이의 용도 |
BR112020025048A2 (pt) | 2018-06-13 | 2021-04-06 | Novartis Ag | Receptores de antígeno quimérico de bcma e usos dos mesmos |
KR102597053B1 (ko) * | 2018-06-26 | 2023-11-02 | 에이비엘바이오 주식회사 | 항-bcma 항체 및 그 용도 |
DE202019005887U1 (de) | 2018-07-03 | 2023-06-14 | Marengo Therapeutics, Inc. | Anti-TCR-Antikörpermoleküle und Verwendungen davon |
MX2021000488A (es) | 2018-07-19 | 2021-04-12 | Regeneron Pharma | Anticuerpos anti-bcma x anti-cd3 biespecificos y usos de estos. |
EP3844265A2 (en) | 2018-08-31 | 2021-07-07 | Novartis AG | Methods of making chimeric antigen receptor-expressing cells |
BR112021003305A2 (pt) | 2018-08-31 | 2021-05-25 | Novartis Ag | métodos para produzir células que expressam receptor de antígeno quimérico |
MX2020011391A (es) * | 2019-01-16 | 2020-11-24 | Caribou Biosciences Inc | Anticuerpo bcma humanizado y linfocitos t car-bcma. |
AU2020229806A1 (en) | 2019-02-25 | 2021-07-29 | Novartis Ag | Mesoporous silica particles compositions for viral delivery |
WO2020191316A1 (en) | 2019-03-21 | 2020-09-24 | Novartis Ag | Car-t cell therapies with enhanced efficacy |
US20220168389A1 (en) | 2019-04-12 | 2022-06-02 | Novartis Ag | Methods of making chimeric antigen receptor-expressing cells |
EP3959320A1 (en) | 2019-04-24 | 2022-03-02 | Novartis AG | Compositions and methods for selective protein degradation |
PE20220336A1 (es) * | 2019-05-03 | 2022-03-14 | Celgene Corp | Conjugado de anticuerpo anti-bcma, composiciones que lo comprenden, y metodos de fabricacion y uso del mismo |
AU2020322588A1 (en) * | 2019-07-30 | 2022-02-03 | Jiangsu Hansoh Pharmaceutical Group Co., Ltd. | Anti-BCMA antibody, antigen-binding fragment thereof and medical use thereof |
JP2022548943A (ja) * | 2019-09-25 | 2022-11-22 | フェイト セラピューティクス,インコーポレイテッド | 複数標的化エフェクター細胞およびその使用 |
AR120566A1 (es) | 2019-11-26 | 2022-02-23 | Novartis Ag | Receptores de antígeno quiméricos y sus usos |
CN112979807B (zh) * | 2019-12-17 | 2022-07-26 | 深圳市菲鹏生物治疗股份有限公司 | Bcma结合抗体及其用途 |
BR112022017148A2 (pt) | 2020-02-27 | 2022-11-08 | Novartis Ag | Métodos para produzir células que expressam receptor de antígeno quimérico |
JP2023515211A (ja) | 2020-02-27 | 2023-04-12 | ノバルティス アーゲー | キメラ抗原受容体発現細胞を作製する方法 |
CN113637073B (zh) * | 2020-05-11 | 2024-04-12 | 上海赛比曼生物科技有限公司 | Bcma抗体及其制备和应用 |
CN116096862A (zh) | 2020-06-11 | 2023-05-09 | 诺华股份有限公司 | Zbtb32抑制剂及其用途 |
MX2023002107A (es) | 2020-08-21 | 2023-03-15 | Novartis Ag | Composiciones y metodos para la generacion in vivo de celulas que expresan car. |
US20230365709A1 (en) | 2020-10-08 | 2023-11-16 | Affimed Gmbh | Trispecific binders |
WO2022094245A1 (en) | 2020-10-30 | 2022-05-05 | Vor Biopharma, Inc. | Compositions and methods for bcma modification |
CN112614596B (zh) * | 2020-12-22 | 2023-01-10 | 厦门承葛生物科技有限公司 | 一种肠道菌群移植治疗溃疡性结肠炎的供受体配型方法 |
CN117597359A (zh) | 2021-04-08 | 2024-02-23 | 马伦戈治疗公司 | 与tcr结合的多功能分子及其用途 |
WO2022229853A1 (en) | 2021-04-27 | 2022-11-03 | Novartis Ag | Viral vector production system |
US11931420B2 (en) | 2021-04-30 | 2024-03-19 | Celgene Corporation | Combination therapies using an anti-BCMA antibody drug conjugate (ADC) in combination with a gamma secretase inhibitor (GSI) |
EP4376958A1 (en) | 2021-07-30 | 2024-06-05 | Affimed GmbH | Duplexbodies |
WO2023019225A2 (en) | 2021-08-11 | 2023-02-16 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce instant blood mediated inflammatory reactions |
AU2022325231A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy to reduce complement-mediated inflammatory reactions |
AU2022326565A1 (en) | 2021-08-11 | 2024-02-08 | Sana Biotechnology, Inc. | Genetically modified cells for allogeneic cell therapy |
IL310691A (en) | 2021-08-11 | 2024-04-01 | Sana Biotechnology Inc | Genetically modified primary cells for allogeneic cell therapy |
TW202323521A (zh) | 2021-08-20 | 2023-06-16 | 瑞士商諾華公司 | 製備表現嵌合抗原受體的細胞之方法 |
TW202334221A (zh) | 2021-11-03 | 2023-09-01 | 德商安富美德有限公司 | 雙特異性cd16a結合劑 |
WO2023158836A1 (en) | 2022-02-17 | 2023-08-24 | Sana Biotechnology, Inc. | Engineered cd47 proteins and uses thereof |
WO2023215725A1 (en) | 2022-05-02 | 2023-11-09 | Fred Hutchinson Cancer Center | Compositions and methods for cellular immunotherapy |
WO2024089639A1 (en) | 2022-10-26 | 2024-05-02 | Novartis Ag | Lentiviral formulations |
WO2024097314A2 (en) | 2022-11-02 | 2024-05-10 | Sana Biotechnology, Inc. | Methods and systems for determining donor cell features and formulating cell therapy products based on cell features |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002066516A2 (en) | 2001-02-20 | 2002-08-29 | Zymogenetics, Inc. | Antibodies that bind both bcma and taci |
AR039067A1 (es) * | 2001-11-09 | 2005-02-09 | Pfizer Prod Inc | Anticuerpos para cd40 |
CA2492671C (en) | 2002-03-22 | 2012-04-17 | Aprogen, Inc. | Humanized antibody and process for preparing same |
ES2354865T3 (es) * | 2005-05-26 | 2011-03-18 | Seattle Genetics, Inc. | Anticuerpos anti-cd40 humanizados y métodos para utilizarlos. |
US9382327B2 (en) * | 2006-10-10 | 2016-07-05 | Vaccinex, Inc. | Anti-CD20 antibodies and methods of use |
WO2009070767A2 (en) * | 2007-11-28 | 2009-06-04 | Whitehead Institute For Biomedical Research | Systemic instigation systems to study tumor growth or metastasis |
JP6061469B2 (ja) * | 2009-03-10 | 2017-01-25 | バイオジェン・エムエイ・インコーポレイテッドBiogen MA Inc. | 抗bcma抗体 |
KR20110124368A (ko) | 2009-04-07 | 2011-11-16 | 로슈 글리카트 아게 | 이중특이적 항―erbb―2/항―c―met 항체 |
JP2014500879A (ja) * | 2010-11-16 | 2014-01-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Bcma発現に相関性を有する疾患を治療する因子及び方法 |
US20130101599A1 (en) * | 2011-04-21 | 2013-04-25 | Boehringer Ingelheim International Gmbh | Bcma-based stratification and therapy for multiple myeloma patients |
HUE063461T2 (hu) | 2011-05-27 | 2024-01-28 | Glaxo Group Ltd | BCMA (CD269/TNFRSF17)-kötõ fehérjék |
EP3508503B1 (en) * | 2012-11-01 | 2022-11-02 | Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft | Antibody against cd269 (bcma) |
NZ725701A (en) * | 2014-04-30 | 2023-09-29 | Max Delbrueck Centrum Fuer Molekulare Medizin Helmholtz Gemeinschaft | Humanized antibodies against cd269 (bcma) |
-
2015
- 2015-04-30 NZ NZ725701A patent/NZ725701A/en unknown
- 2015-04-30 JP JP2016565168A patent/JP6755805B2/ja active Active
- 2015-04-30 UA UAA201612087A patent/UA121031C2/uk unknown
- 2015-04-30 KR KR1020227018383A patent/KR102526945B1/ko active IP Right Grant
- 2015-04-30 CA CA2944962A patent/CA2944962A1/en active Pending
- 2015-04-30 AU AU2015254526A patent/AU2015254526B2/en active Active
- 2015-04-30 CN CN201580021693.5A patent/CN106661109B/zh active Active
- 2015-04-30 US US15/306,438 patent/US10144782B2/en active Active
- 2015-04-30 WO PCT/EP2015/059562 patent/WO2015166073A1/en active Application Filing
- 2015-04-30 IL IL303667A patent/IL303667A/en unknown
- 2015-04-30 RU RU2021115081A patent/RU2021115081A/ru unknown
- 2015-04-30 KR KR1020237013978A patent/KR102632731B1/ko active IP Right Grant
- 2015-04-30 RU RU2016146486A patent/RU2749041C2/ru active
- 2015-04-30 BR BR112016024546-6A patent/BR112016024546A2/pt not_active Application Discontinuation
- 2015-04-30 IL IL248257A patent/IL248257B1/en unknown
- 2015-04-30 EP EP15720954.5A patent/EP3137500A1/en active Pending
- 2015-04-30 MX MX2016013767A patent/MX2016013767A/es active IP Right Grant
- 2015-04-30 SG SG11201608415QA patent/SG11201608415QA/en unknown
- 2015-04-30 KR KR1020167033409A patent/KR102405492B1/ko active IP Right Grant
- 2015-04-30 CN CN202110761923.9A patent/CN113491776A/zh active Pending
-
2016
- 2016-10-12 ZA ZA2016/07018A patent/ZA201607018B/en unknown
- 2016-10-20 MX MX2020010530A patent/MX2020010530A/es unknown
-
2018
- 2018-10-25 US US16/170,575 patent/US10851172B2/en active Active
-
2020
- 2020-08-26 JP JP2020142486A patent/JP7189913B2/ja active Active
- 2020-10-23 US US17/079,075 patent/US11820829B2/en active Active
-
2022
- 2022-12-05 JP JP2022194533A patent/JP2023025202A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112016024546A2 (pt) | anticorpo ou fragmento de anticorpo, anticorpo ou fragmento de anticorpo isolado, conjugado de anticorpo-fármaco, molécula de ácido nucleico, célula hospedeira, e, composição farmacêutica | |
BR112019011582A2 (pt) | anticorpos e métodos de utilização dos mesmos | |
PE20160953A1 (es) | Anticuerpo pd-1, fragmento de union al antigeno de este y uso medico de este | |
BR112017025529A2 (pt) | agentes de ligação ao tigit e usos destes | |
PH12017500803A1 (en) | Anti-pd-1 antibodies | |
BR112019010265A2 (pt) | anticorpos anti_cd137 inovadores e usos dos mesmos | |
PH12017500890A1 (en) | Antibody drug conjugates | |
BR112018014615A2 (pt) | composições de anticorpo para ror1 e métodos relacionados | |
BR112019012354A2 (pt) | anticorpos apenas de cadeia pesada anti-bcma | |
BR112016015677A2 (pt) | Moléculas de anticorpo isoladas capazes de se ligarem à pd-1 humana, bem como seu método de produção e seu uso, composições farmacêuticas, ácido nucleico, vetor de expressão, célula hospedeira, e método para detecção de pd-1 em uma amostra biológica | |
PH12017500002A1 (en) | Anti-cdh6 antibody drug conjugates | |
BR112018070187A8 (pt) | receptores quiméricos para flt3 e seus métodos de uso | |
BR112018014028A2 (pt) | anticorpos monoclonais anti-cd47 humanizados, de camundongo ou quimérico | |
JOP20160131B1 (ar) | الأجسام المضادة للعامل xi وطرق الاستخدام | |
BR112017017727A2 (pt) | heterociclos bicíclicos como inibidores de fgfr4 | |
AU2016264323A8 (en) | Compositions and methods for TCR reprogramming using fusion proteins | |
EP4249066A3 (en) | Antibodies to tigit | |
BR112017009398A2 (pt) | moléculas de ligação específicas para cd73 e seus usos | |
WO2015109124A3 (en) | Immunomodulatory agents | |
BR112016022814A8 (pt) | composição farmacêutica e seu método de preparação, ácido nucleico, e dispositivo médico ou kit médico | |
BR112019024654A2 (pt) | proteína de ligação nkg2d, cd16 e ror1 ou ror2 | |
BR112016016916A8 (pt) | uso de um anticorpo que se liga à calicreína plasmática ativa para tratamento de angiodema hereditário (hae) | |
PH12019500571A1 (en) | Anti-pd-1 antibodies | |
EA201892774A1 (ru) | Антитела | |
BR112016002401A2 (pt) | métodos para reduzir as taxas de exacerbação de asma usando benralizumab |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09B | Patent application refused [chapter 9.2 patent gazette] | ||
B12B | Appeal against refusal [chapter 12.2 patent gazette] |